Sheng-Yong Wang
Nephrology · San Jose, CANPI 1700813318
Payments from drug & device makers
Across 346 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$728
- Amarin Pharma, Inc.$713
- Fresenius USA Marketing, Inc.$556
- Novo Nordisk$536
- OPKO Pharmaceuticals, LLC$445
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,21193%
- Education$5157%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 53 | $1,280 |
| AstraZeneca(2 entities) | 33 | $728 |
| Amarin Pharma, Inc. | 37 | $713 |
| Fresenius USA Marketing, Inc. | 26 | $556 |
| Novo Nordisk | 28 | $536 |
| OPKO Pharmaceuticals, LLC | 27 | $445 |
| Bayer | 17 | $410 |
| Lilly USA, LLC | 15 | $400 |
| Travere Therapeutics, Inc. | 19 | $340 |
| Boehringer Ingelheim | 6 | $249 |
| Mallinckrodt Hospital Products Inc. | 8 | $232 |
| Vifor Pharma, Inc. | 11 | $225 |
| Calliditas Therapeutics US Inc. | 9 | $207 |
| ANI Pharmaceuticals, Inc. | 9 | $198 |
| GSK | 6 | $163 |
| Novartis | 6 | $155 |
| Ardelyx, Inc. | 6 | $119 |
| Aurinia Pharma U.S., Inc. | 4 | $104 |
| Baxter Healthcare | 1 | $100 |
| Pfizer | 4 | $94 |
| Sanofi | 4 | $94 |
| Ultragenyx Pharmaceutical Inc. | 4 | $93 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Johnson & Johnson | 2 | $45 |
| Mallinckrodt Enterprises LLC | 2 | $33 |
| Eisai Inc. | 1 | $29 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Ascend Therapeutics US, LLC | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Merck | 1 | $20 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Parsabiv$125
- JARDIANCE$123
- Vascepa$123
- Ozempic$116
- Renal - PD$100
How this compares
$7,725 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $130,631 |
| VascepaIcosapent Ethyl | 202 | $102,963 |
| Icosapent Ethyl | 284 | $90,642 |
| KerendiaFinerenone | 90 | $87,227 |
| RayaldeeCalcifediol | 45 | $74,727 |
| JardianceEmpagliflozin | 81 | $69,508 |
| ProliaDenosumab | 39 | $65,785 |
| TrulicityDulaglutide | 59 | $65,415 |
| VeltassaPatiromer Calcium Sorbitex | 40 | $62,416 |
| VelphoroSucroferric Oxyhydroxide | 12 | $62,216 |
| OzempicSemaglutide | 34 | $52,472 |
| JanuviaSitagliptin Phosphate | 61 | $50,286 |
| LokelmaSodium Zirconium Cyclosilicate | 49 | $48,473 |
| ProcritEpoetin Alfa | 45 | $47,528 |
| FarxigaDapagliflozin Propanediol | 44 | $45,646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Retacrit | $94 | $141,634164 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Synjardy | $249 | $125,934154 claims |
| AstraZenecaLokelma, Farxiga | $728 | $94,11993 claims |
| BayerKerendia | $410 | $87,22790 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $445 | $74,72745 claims |
| Novo NordiskOzempic, Rybelsus | $536 | $74,04254 claims |
| AmgenProlia, Epogen | $1,280 | $70,50154 claims |
| Johnson & JohnsonProcrit, Xarelto | $45 | $69,32371 claims |
| Lilly USA, LLCTrulicity | $400 | $65,41559 claims |
| Fresenius USA Marketing, Inc.Velphoro | $556 | $62,21612 claims |
| MerckJanuvia, Janumet | $20 | $59,02973 claims |
| GSKBreo Ellipta | $163 | $11,78325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,341 nephrology providers in California.
Other nephrology in San Jose
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.